Company CVAbout Biocon Ltd. 
Biocon Ltd.
Large Cap
Pharmaceuticals & Drugs
Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
Company Coordinates
Company Details
20th KM Hosur Road Hebbagodi, Electronic City P O Bangalore Karnataka : 560100
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 600.30 Cr
Number of Shares
120.06 Cr
Face Value
INR 5.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
28-Apr-2021
120.06
600.30
600000
5
Issued under ESOP Scheme
12-Jun-2019
12
600.00
600000000
5
Bonus
15-Jun-2017
6
300.00
400000000
5
Bonus
15-Jun-2017
6
300.00
400000000
5
Bonus
11-Sep-2008
2
100.00
100000000
5
Bonus
11-Sep-2008
2
100.00
100000000
5
Bonus
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 29 Schemes (8.58%)
FIIs
Held by 239 FIIs (5.66%)
Promoter with highest holding
Kiran Mazumdar Shaw (40.36%)
Highest Public shareholder
Life Insurance Corporation Of India (5.34%)
Individual Investors Holdings
14.07%
Board of Directors
Management
Designation
Remuneration
Kiran Mazumdar Shaw
Chairperson
3.0 cr
Ravi Mazumdar
Director
58.7 lacs
Vijay Kumar Kuchroo
Independent Director
54.0 lacs
M Damodaran
Independent Director
59.9 lacs
Bobby Parikh
Independent Director
74.2 lacs
Mayank Verma
Company Sec. & Compli. Officer
0
SIDDHARTH MITTAL
Managing Director & CEO
4.79 cr
Eric Vivek Mazumdar
Director
52.7 lacs
Naina Lal Kidwai
Independent Director
64.8 lacs
Peter John Bains
Independent Director
32.8 lacs
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Purchase & Finished Goods
1.7
0%
Purchase & Finished Goods
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Finished Goods - Biopharmaceuticals/Formulations
2,424.00
84.03%
Other Operating Revenue - Others
229.40
7.95%
Traded Goods - Formulations/Biopharmaceuticals
215.20
7.46%
Finished Goods - Biopharmaceuticals/Formulations
Finished Goods - Biopharmaceuticals/Formulations
Other Operating Revenue - Others
Other Operating Revenue - Others
Traded Goods - Formulations/Biopharmaceuticals
Traded Goods - Formulations/Biopharmaceuticals
Stock DNARevenue and Profits:
Net Sales:
3,821 Cr
(Quarterly Results - Dec 2024)
Net Profit:
25 Cr
Pharmaceuticals & Drugs
INR 38,167 Cr (Large Cap)
48.00
33
0.16%
0.67
6.64%
1.75
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
